Summary of ABEO Q2 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: Abeona reported net revenue of $11.4 million for Q2 2026, a 31% increase from Q1 2026's $8.7 million. Revenue was recognized for 4 out of 5 patients treated, as one batch did not meet revenue recognition thresholds due to low yield.

Expenses:

R&D Expenses: $5 million, down from $9.6 million in Q1 2026 (which included a one-time $7 million cost for in-licensing).

SG&A Expenses: $15.8 million, reduced from $19.5 million in Q1 2026, attributed to fewer engineering runs and manufacturing training costs.

Net Loss: Reported at $20.2 million or $0.35 per share, compared to a net loss of $17.1 million in Q1 2026.

Cash Position: As of June 30, 2026, cash, cash equivalents, and short-term investments totaled $146.8 million.

2Strategic Updates and Business Highlights

Commercial Progress: The rollout of ZEVASKYN is advancing with the activation of 7 Qualified Treatment Centers (QTCs), including the recent addition of Cincinnati Children's Hospital.

Patient Engagement: 12 patients have been treated since launch, with 5 in Q2 2026 and 3 more in Q3 to date. The company is focusing on increasing patient awareness and engagement through community events.

NTAP Status: Abeona received New Technology Add-On Payment (NTAP) status from CMS effective October 1, 2026, which is expected to enhance reimbursement for hospitals treating Medicare patients.

3Forward Guidance and Outlook

Abeona aims to maintain a steady growth trajectory by expanding its QTC network and improving patient access. The company anticipates that as more QTCs become operational, the cadence of patient treatments will increase, with a target of 1 patient per month per QTC once steady state is achieved.

The company is focused on achieving a sustainable cash flow positive business model through consistent patient treatments.

4Bad News, Challenges, or Points of Concern

Manufacturing Issues: The company faced challenges with manufacturing yields, reporting a low-yield batch and an out-of-spec batch that impacted revenue recognition. This raises concerns about the reliability of the manufacturing process.

Patient Cancellations: There were instances of last-minute cancellations due to patient health deterioration, which could affect treatment timelines and patient throughput.

Operational Complexity: The unique operational requirements of ZEVASKYN, including the need for real-time coordination among multiple stakeholders, have led to scheduling disruptions and variability in treatment timelines.

5Notable Q&A Insights

Patient Treatment Cadence: QTCs are expected to reach a steady state of treating 1 patient per month, but this varies significantly by center.

Manufacturing Yield Concerns: The company views recent manufacturing issues as isolated incidents but acknowledges the need for ongoing process improvements.

Patient Accessibility: Having in-state QTCs is crucial for faster patient access, especially for Medicaid patients. The company is working to expand its network to improve overall patient access.

Revenue and Margin Expectations: Gross margins are expected to improve as patient volumes increase, with a target of 85% to 90% once full operating capacity is reached. Overall, while Abeona is making progress in its commercial rollout and has received important regulatory recognition, it faces challenges in manufacturing reliability and patient treatment logistics that could impact future performance.